Comparative effectiveness research in first-line therapies for untreated multiple myeloma

Research Project

Project/Area Number	23791092
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Hematology
Research Institution	Fujita Health University
Principal Investigator	TERASAWA Teruhiko 藤田保健衛生大学, 医学部, 准教授 (30399597)
Research Collaborator	NAGAI Hirokazu 国立病院機構名古屋医療センター, 臨床研究センター, 部長 (30360811)
Project Period (FY)	2011 – 2012
Project Status	Completed (Fiscal Year 2012)
Budget Amount *help	¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000) Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Keywords	血液腫瘍学 / 多発性骨髄腫 / 比較効果研究 / メタアナリシス / 国際情報交換 / 国際情報交流、米国
Research Abstract	Currently available first-line therapies for untreated multiple myeloma consist of conventional chemotherapies, high-dose chemotherapies followed by autologous stem-cell transplantation, and novel agents-based therapies, which are selected on the basis of important clinical factors such as age, and biochemical, cytogenetic, and molecular markers. We performed systematic reviews and meta-analyses to evaluate comparative efficacy of these therapeutic strategies, and critically appraised the evidence on the prognostic factors.